Back to results
US 2026/0306411 A1Published application
Pharmaceutical oral dosage form of q203
AssigneeQurient Co., Ltd.
InventorsKIYEAN NAM, JAESEUNG KIM, CHUNWON JUNG, SAEYEON LEE
Life of this patent
Estimating the term…
Abstract
The present invention relates to new pharmaceutical dosage forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide, in particular of its ditosylate form.
Claims25
A pharmaceutical oral dosage form of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate, said dosage form comprising a mixture of:
- a) granules comprising 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl) piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate, at least one intragranular pharmaceutically acceptable excipient, and a solubilizer;
- and
- b) a blend surrounding said granules and comprising at least one binder, at least one lubricant and at least one disintegrant, and optionally a filler.
Dependencies are inferred from the claim text.